(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for 6 Hot Brilliant Beds - 2Figure out how to Amplify Your Open Record Reward
- 3India’s delayed climate plan sets modest emission target
- 4I thought I knew the night sky, but what I saw from the Canary Islands left me speechless
- 5Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Figure out How to Augment Your Rooftop Substitution Speculation
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Computerized Strengthening d: A Survey of \Upgrading Efficiency\ Programming Application
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- Exhaustive Experiences into Prudent Senior Living in the UK
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Cyber Monday 2025 streaming deal: Get $42 off six months of Apple TV
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- An Artemis 2 astronaut took a 'bath' on camera on the way to the moon. Mission Control's reaction was priceless (video)
